Elobixibat

Elobixibat

Clinical data
Routes of administration	Oral
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-{(2R)-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylacetyl}glycine
CAS Number	439087-18-0
PubChem (CID)	9939892
ChemSpider	8115513
UNII	865UEK4EJC
ChEMBL	CHEMBL3039515
Chemical and physical data
Formula	C36H45N3O7S2
Molar mass	695.89 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(O)CNC(=O)[C@@H](c1ccccc1)NC(=O)COc4cc3c(N(c2ccccc2)CC(CS3(=O)=O)(CCCC)CCCC)cc4SC
InChI InChI=InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1 Key:XFLQIRAKKLNXRQ-UUWRZZSWSA-N

Elobixibat is an IBAT inhibitor,^[1] undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C).

Mechanism of action

IBAT is the bile acid:sodium symporter responsible for the reuptake of bile acids in the ileum which is the initial step in the enterohepatic circulation. By inhibiting the uptake of bile acids, elobixibat increases the bile acid concentration in the gut, and this accelerates intestinal passage and softens the stool. Following several phase II studies, it is now undergoing phase III trials.^[2]

Drug development

The drug was developed by Albireo AB, who licensed it to Ferring Pharmaceuticals for further development and marketing.^[3][4] Albireo has partnered with Ajinomoto Pharmaceuticals, giving the Japan-based company the rights to further develop the drug and market it throughout Asia.^[5]

References

1. "INN for A3309 is ELOBIXIBAT". AlbireoPharma. Retrieved 5 December 2012.
2. Acosta A, Camilleri M (2014). "Elobixibat and its potential role in chronic idiopathic constipation". Therap Adv Gastroenterol. 7 (4): 167–75. doi:10.1177/1756283X14528269. PMC 4107709. PMID 25057297.
3. H. Spreitzer (27 August 2012). "Neue Wirkstoffe – Elobixibat". Österreichische Apothekerzeitung (in German) (18/2012): 24.
4. "Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB" (Press release). Ferring Pharmaceuticals. 3 July 2012.
5. "Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat". Albireo. Retrieved 5 December 2012.